• “Immune cell activation in the tumor and inhibition of metastasis with an oral, infrequently administered and well tolerated small molecule provides an attractive treatment option for patients. Immune activation is recognized as an important requirement to achieve durable and complete remissions in conjunction with standard-of-care therapies,” said El-Deiry. “We discovered ONC201 through its ability to stimulate TRAIL pathway signaling that now provides a mechanistic explanation for immune cell activation.”

    Please see the following link for the full article: